These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 33278018

  • 1. Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists.
    Lastennet D, Mariani LL, Rascol O, Turc JD, Alfaisal H, Lapeyre-Mestre M, Corvol JC, Tubach F.
    CNS Drugs; 2020 Dec; 34(12):1267-1274. PubMed ID: 33278018
    [Abstract] [Full Text] [Related]

  • 2. Survey of the use of domperidone and the association with QTc prolongation in general practice.
    Ioannou A, Jain A, Kassianos G, Missouris C.
    Postgrad Med J; 2016 Jul; 92(1089):390-2. PubMed ID: 26802127
    [Abstract] [Full Text] [Related]

  • 3. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
    Tison F, Wiart L, Guatterie M, Fouillet N, Lozano V, Henry P, Barat M.
    Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
    [Abstract] [Full Text] [Related]

  • 4. Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK.
    Simeonova M, de Vries F, Pouwels S, Driessen JHM, Leufkens HGM, Cadarette SM, Burden AM.
    Br J Clin Pharmacol; 2018 Nov; 84(11):2551-2561. PubMed ID: 29975795
    [Abstract] [Full Text] [Related]

  • 5. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D.
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [Abstract] [Full Text] [Related]

  • 6. Domperidone for Hypotension in Parkinson's Disease: A Systematic Review.
    Bacchi S, Chim I, Kramer P, Postuma RB.
    J Parkinsons Dis; 2017 Jun; 7(4):603-617. PubMed ID: 29103053
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine.
    Sigurdardóttir GR, Nilsson C, Odin P, Grabowski M.
    Acta Neurol Scand; 2001 Aug; 104(2):92-6. PubMed ID: 11493225
    [Abstract] [Full Text] [Related]

  • 8. Current approaches for the management of Parkinson's disease in Chinese hospitals: a cross-sectional survey.
    Wang G, Cui HL, Liu J, Xiao Q, Wang Y, Ma JF, Zhou HY, Pan J, Tan YY, Chen SD, Chinese Movement Disorders Society.
    BMC Neurol; 2018 Aug 22; 18(1):122. PubMed ID: 30134845
    [Abstract] [Full Text] [Related]

  • 9. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST, Woodward WR, Nutt JG.
    Clin Neuropharmacol; 1996 Feb 22; 19(1):59-64. PubMed ID: 8867518
    [Abstract] [Full Text] [Related]

  • 10. Clinical practice regarding dopamine-agonist use and driving in Parkinson's disease.
    de Bie RM, Miyasaki J, Lang AE, Fox SH.
    Can J Neurol Sci; 2007 Nov 22; 34(4):438-42. PubMed ID: 18062452
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.
    Merello M, Pirtosek Z, Bishop S, Lees AJ.
    Clin Auton Res; 1992 Aug 22; 2(4):215-9. PubMed ID: 1392539
    [Abstract] [Full Text] [Related]

  • 12. Domperidone for insufficient lactation in England 2002-2015: A drug utilization study with interrupted time series analysis.
    Mehrabadi A, Reynier P, Platt RW, Filion KB.
    Pharmacoepidemiol Drug Saf; 2018 Dec 22; 27(12):1316-1324. PubMed ID: 30106193
    [Abstract] [Full Text] [Related]

  • 13. Sublingual apomorphine solution in Parkinson's disease.
    Panegyres PK, Graham SJ, Williams BK, Higgins BM, Morris JG.
    Med J Aust; 1991 Sep 16; 155(6):371-4. PubMed ID: 1921784
    [Abstract] [Full Text] [Related]

  • 14. Discussing sexuality with patients with Parkinson's disease: a survey among Dutch neurologists.
    van Hees PJ, van der Plas AA, van Ek GF, Putter H, Den Oudsten BL, den Ouden ME, Elzevier HW.
    J Neural Transm (Vienna); 2017 Mar 16; 124(3):361-368. PubMed ID: 27885433
    [Abstract] [Full Text] [Related]

  • 15. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D, CTH-300 Study investigators.
    Lancet Neurol; 2020 Feb 16; 19(2):135-144. PubMed ID: 31818699
    [Abstract] [Full Text] [Related]

  • 16. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
    Albanese A, Bonuccelli U, Brefel C, Chaudhuri KR, Colosimo C, Eichhorn T, Melamed E, Pollak P, Van Laar T, Zappia M.
    Mov Disord; 2001 Mar 16; 16(2):197-201. PubMed ID: 11295770
    [Abstract] [Full Text] [Related]

  • 17. Impact of Safety Warning on Domperidone Prescribing for Geriatric Patients in South Korea: Analysis of National Insurance Claim Data.
    Rhew K, Han N, Oh JM.
    Int J Environ Res Public Health; 2019 Aug 20; 16(16):. PubMed ID: 31434200
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.
    Corsini GU, Del Zompo M, Gessa GL, Mangoni A.
    Lancet; 1979 May 05; 1(8123):954-6. PubMed ID: 87620
    [Abstract] [Full Text] [Related]

  • 19. Domperidone Prescribing Practices Exposed Patients to Cardiac Risk despite a "Black Box" Warning: A Canadian Tertiary Care Center Study.
    Forbes N, Cooray M, Al-Dabbagh R, Yuan Y, Tse F, Liu LW, Xenodemetropoulos T.
    Can J Gastroenterol Hepatol; 2016 May 05; 2016():2937678. PubMed ID: 27446835
    [Abstract] [Full Text] [Related]

  • 20. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 May 05; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.